<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Krogsgaard | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/shoepuffin41/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/shoepuffin41/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Krogsgaard.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">04db64ed027d29c1355f0038a5d52364</guid>
				<title>Krogsgaard posted an update: The estimated pulse-wave velocity (ePWV) as measure for [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/42240/</link>
				<pubDate>Sun, 09 Feb 2025 08:32:39 -0800</pubDate>

									<content:encoded><![CDATA[<p>The estimated pulse-wave velocity (ePWV) as measure for arterial wall stiffness is associated with an increased risk of cardiovascular disease (CVDs) and all-cause death in Western populations. We investigated the association between ePWV and the incidence of CVDs (myocardial infarction, cerebral infarction, cerebral hemorrhage) and all-cause&hellip;<span class="activity-read-more" id="activity-read-more-42240"><a href="http://www.nationalboardinstitute.com/activity/p/42240/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">24908c453133f60743ea6ebb73705354</guid>
				<title>Krogsgaard posted an update: Then we outlined potential biomarkers to assess the changes [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/41368/</link>
				<pubDate>Sat, 08 Feb 2025 08:35:40 -0800</pubDate>

									<content:encoded><![CDATA[<p>Then we outlined potential biomarkers to assess the changes in the micro-environment and monitor biochemical pathway suppression. This suppression-centric aim targets these mechanisms of growth with the goal of potentially halting tumor growth and preventing cancer cell metabolic adaptation. <a href="https://www.selleckchem.com/products/dl-alanine.html" rel="nofollow ugc">DL-Alanine nmr</a> We chose TNBC to demonstrate this 5-step&hellip;<span class="activity-read-more" id="activity-read-more-41368"><a href="http://www.nationalboardinstitute.com/activity/p/41368/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">c5a6cfac53735f9a0f1335b674c36e9e</guid>
				<title>Krogsgaard posted an update: Neuropathic pain affects ~ 6.9-10% of the general population [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/38761/</link>
				<pubDate>Wed, 05 Feb 2025 08:25:38 -0800</pubDate>

									<content:encoded><![CDATA[<p>Neuropathic pain affects ~ 6.9-10% of the general population and leads to loss of function, anxiety, depression, sleep disturbance, and impaired cognition. Here, we report the safety, tolerability, and pharmacokinetics of a voltage-dependent and use-dependent sodium channel blocker, vixotrigine, currently under investigation for the treatment of&hellip;<span class="activity-read-more" id="activity-read-more-38761"><a href="http://www.nationalboardinstitute.com/activity/p/38761/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">72439678842c4772bf77fac239acb2d7</guid>
				<title>Krogsgaard posted an update: th KCD.







 We found that age at diagnosis, race, AJCC T [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/35184/</link>
				<pubDate>Sat, 01 Feb 2025 08:36:31 -0800</pubDate>

									<content:encoded><![CDATA[<p>th KCD.</p>
<p> We found that age at diagnosis, race, AJCC T status and chemotherapy as the independent risk factors associated with CCD were different from those associated with KCD.</p>
<p>We found that age at diagnosis, race, AJCC T status and chemotherapy as the independent risk factors associated with CCD were different from those associated with&hellip;<span class="activity-read-more" id="activity-read-more-35184"><a href="http://www.nationalboardinstitute.com/activity/p/35184/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">563a73dcfb0e54b3fb6d43efe82f84b4</guid>
				<title>Krogsgaard posted an update: 93%; 95% CI 2.15-11.25%), followed by peroneal nerve palsy [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/32855/</link>
				<pubDate>Wed, 29 Jan 2025 08:33:59 -0800</pubDate>

									<content:encoded><![CDATA[<p>93%; 95% CI 2.15-11.25%), followed by peroneal nerve palsy (2.25%; 95% CI 0.14-6.14%), fracture (0.56%; 95% CI 0-1.74%), and recurrent deformity (0.54%; 95% CI 0-1.74%). Furthermore, PFO was also associated with improved medial/lateral joint space ratio (MD 0.17; 95% CI 0.15-0.19).</p>
<p> PFO yielded promising prospects in the management of&hellip;<span class="activity-read-more" id="activity-read-more-32855"><a href="http://www.nationalboardinstitute.com/activity/p/32855/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">806a4e1969d88f529ec956339dd44459</guid>
				<title>Krogsgaard posted an update: Enormous variability in speech recognition outcomes persists [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28236/</link>
				<pubDate>Tue, 28 Jan 2025 10:43:41 -0800</pubDate>

									<content:encoded><![CDATA[<p>Enormous variability in speech recognition outcomes persists in adults who receive cochlear implants (CIs), which leads to a barrier to progress in predicting outcomes before surgery, explaining &#8220;poor&#8221; outcomes, and determining how to provide tailored rehabilitation therapy for individual CI users. The primary goal of my research program over the&hellip;<span class="activity-read-more" id="activity-read-more-28236"><a href="http://www.nationalboardinstitute.com/activity/p/28236/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">3c4b2fcb3a394904da9d7ca1da70ab27</guid>
				<title>Krogsgaard became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/28198/</link>
				<pubDate>Tue, 28 Jan 2025 10:39:45 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>